DOI: 10.1002/mco2.481 ISSN: 2688-2663

Drug development advances in human genetics‐based targets

Xiaoxia Zhang, Wenjun Yu, Yan Li, Aiping Wang, Haiqiang Cao, Yuanlei Fu
  • Cell Biology
  • Biochemistry (medical)
  • Genetics (clinical)
  • Computer Science Applications
  • Drug Discovery
  • Genetics
  • Oncology
  • Immunology and Allergy


Drug development is a long and costly process, with a high degree of uncertainty from the identification of a drug target to its market launch. Targeted drugs supported by human genetic evidence are expected to enter phase II/III clinical trials or be approved for marketing more quickly, speeding up the drug development process. Currently, genetic data and technologies such as genome‐wide association studies (GWAS), whole‐exome sequencing (WES), and whole‐genome sequencing (WGS) have identified and validated many potential molecular targets associated with diseases. This review describes the structure, molecular biology, and drug development of human genetics‐based validated beneficial loss‐of‐function (LOF) mutation targets (target mutations that reduce disease incidence) over the past decade. The feasibility of eight beneficial LOF mutation targets (PCSK9, ANGPTL3, ASGR1, HSD17B13, KHK, CIDEB, GPR75, and INHBE) as targets for drug discovery is mainly emphasized, and their research prospects and challenges are discussed. In conclusion, we expect that this review will inspire more researchers to use human genetics and genomics to support the discovery of novel therapeutic drugs and the direction of clinical development, which will contribute to the development of new drug discovery and drug repurposing.

More from our Archive